Update : Medivir AB and Idenix Announce Phase-2 Results with - TopicsExpress



          

Update : Medivir AB and Idenix Announce Phase-2 Results with Simeprevir, Ribavirin, and Samatasvir in Treating Hepatitis C On January 13, Medivir AB announced sustained viral response 4 weeks after the end of therapy (SVR4) in the HELIX-1 phase-2 clinical trial. The announcement of SVR4 results comes parallel to SVR4 results with another combination treatment—VX-135 and daclatasvir—through a partnership between Vertex and Bristol-Myers Squibb. Medivir’s simeprevir and Idenix’s samatasvir (IDX719) with ribavirin background therapy is unlike the combination under development by Vertex and Bristol-Myers Squibb, however, in that samatasvir and simeprevir are used with ribavirin, whereas the VX-135 and daclatasvir combination is not used with ribavirin. In the phase II trial, patients received 12 weeks of therapy with simeprevir, ribavirin, and samatasvir to attain an 85% rate of SVR4 in 17 of 20 patients with genotype-1b or -4 hepatitis C virus. The ongoing HELIX trials will evaluate whether this 4-week response rate remains durable through a 12- or 24-week endpoint, which is the standard of evaluating functional cure rates in hepatitis C therapy. details @ specialtypharmacytimes/news/Medivir-AB-and-Idenix-Announce-Phase-2-Results-with-Simeprevir-Ribavirin-and-Samatasvir-in-Treating-Hepatitis-C
Posted on: Sat, 01 Feb 2014 07:18:17 +0000

Trending Topics



Recently Viewed Topics




© 2015